BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1430@pharmaconomics
DTSTAMP:20260707T020020Z
DTSTART;VALUE=DATE:20260411
DTEND;VALUE=DATE:20260412
SUMMARY:BNTX Phase 2 — trastuzumab pamirtecan
DESCRIPTION:Phase 2 trial results for trastuzumab pamirtecan in endometrial cancer are due Apr 11\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1776985/000177698526000027/a991260410_tpamecdataxsgo2.htm\n\nTrack it: https://pharmaconomics.com/e/1430
URL:https://pharmaconomics.com/e/1430
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BNTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR